Tokyo, Japan

Yoshihisa Iida

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yoshihisa Iida: Innovator in Keratoconjunctival Health

Introduction

Yoshihisa Iida is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of ophthalmology, particularly in the development of protective agents for the keratoconjunctiva. His innovative work has the potential to improve the quality of life for individuals suffering from keratoconjunctival disorders.

Latest Patents

Yoshihisa Iida holds a patent for a protective agent for the keratoconjunctiva or a suppressive agent for keratoconjunctival disorders. The patent focuses on the use of glucosylglycerol as an active ingredient, which has shown an excellent suppressive effect on keratoconjunctival disorders. This invention not only provides a method for protecting the keratoconjunctiva but also offers a pharmaceutical application for those affected by such disorders. He has 1 patent to his name.

Career Highlights

Throughout his career, Yoshihisa Iida has worked with prominent companies in the pharmaceutical and sugar refining industries. He has been associated with Toyo Sugar Refining Co., Ltd. and Otsuka Pharmaceutical Factory, Inc. His experience in these organizations has contributed to his expertise in developing innovative solutions for health-related issues.

Collaborations

Yoshihisa Iida has collaborated with notable professionals in his field, including Kyo Aizawa and Takashi Shimoida. These collaborations have likely enhanced his research and development efforts, leading to advancements in keratoconjunctival health.

Conclusion

Yoshihisa Iida's contributions to the field of ophthalmology through his innovative patent demonstrate his commitment to improving health outcomes. His work with glucosylglycerol as a protective agent for the keratoconjunctiva showcases the potential for advancements in treating keratoconjunctival disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…